Breaking News

Moderna Spikevax Receives Marketing Authorization in Korea

The Moderna COVID-19 vaccine manufactured at Samsung Biologics’ local production facilities can be distributed in Korea and exported to other countries.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna received marketing authorization from the Ministry of Food and Drug Safety of Korea (MFDS) for Spikevax, Moderna’s COVID-19 vaccine (mRNA-1273) manufactured by Samsung Biologics, a global CDMO providing integrated contract development and manufacturing services.    This marketing authorization allows the Moderna COVID-19 vaccine manufactured at Samsung Biologics’ local pharmaceutical production facilities to be distributed within Korea and exported to other countries.   In May 2021, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters